Practical semaglutide advice before you begin treatment

You've decided to look into it, here's what happens next

Most people arrive at this point after months of trying other approaches, or after hearing about Wegovy from a GP, a colleague or something they read online. The first thing worth knowing is that semaglutide is not a supplement or a lifestyle product: it is a prescription-only medicine regulated by the MHRA, and accessing it legally requires a clinical consultation with a prescriber who can review your medical history.

That process matters more than it might seem. A prescriber will check for contraindications (including a personal or family history of medullary thyroid carcinoma, pancreatitis, or certain inflammatory bowel conditions) and will consider whether semaglutide fits alongside any other medicines you take. At nume, every consultation is read personally by a GPhC-registered Independent Prescriber, not processed by an algorithm. You'll know the same day whether treatment is clinically suitable for you.

One practical thing our prescribers hear often: people submit their consultation on a Monday morning, relieved to have finally acted, and are surprised when the pen arrives Tuesday. That timing works well if you order before the 12pm cut-off on a working day; if payday lands on a Friday and you want to start the following week, placing the order before midday that Friday means your treatment is dispatched the same day, subject to approval.

What the semaglutide dose schedule actually means in practice

The dosing pathway for Wegovy begins at 0.25mg per week, moving up through 0.5mg, 1mg, 1.7mg and eventually to a 2.4mg maintenance dose, with roughly four weeks at each level. A newer 7.2mg maintenance option was approved by the MHRA in January 2026, initially using multiple standard pens, with a dedicated single-dose 7.2mg pen approved in April 2026.

The starting dose is not where the therapeutic effect lives, its job is to give your digestive system time to adapt before the dose does meaningful work. People sometimes feel frustrated that progress feels slow in the first month. That's by design. Rushing the schedule increases side-effect burden without improving outcomes. If you are considering higher doses later in treatment, those decisions are made jointly with your prescriber, based on how you're tolerating the current dose and whether weight loss is progressing.

For a broader overview of how the medicine works and what to expect across the full programme, the semaglutide overview page covers the mechanism in detail, including what distinguishes it from tirzepatide (Mounjaro), which activates a second receptor pathway. If you want to look at specific points in the dose schedule, you can read about how semaglutide 1mg fits into the step-up programme or explore what moving to semaglutide 2mg means for your treatment.

The side effects worth preparing for, and the ones that warrant urgent attention

Nausea is the side effect people ask about most. It is common, particularly in the first few weeks and after each dose increase, but it is usually manageable rather than severe. Eating smaller portions, avoiding rich or fatty meals and staying well hydrated all help. Constipation catches some people off guard; increasing fibre and fluid intake early tends to reduce its impact.

More serious, though much rarer, is acute pancreatitis. In January 2026, the MHRA issued a Drug Safety Update specifically highlighting this risk for GLP-1 medicines: severe, persistent abdominal pain (especially pain that spreads to the back) with or without vomiting is a symptom that needs same-day emergency assessment, not a wait-and-see approach. Stop the injection and seek urgent medical help.

Women using oral contraceptives should be aware that semaglutide can slow gastric emptying, which in principle might affect pill absorption. The NHS advises discussing contraceptive choice with your prescriber before starting treatment. If you are pregnant, trying to conceive, or breastfeeding, semaglutide is not recommended; the same applies for anyone under 18.

Side effects can be reported directly to the MHRA via the Yellow Card scheme, this is valuable for a Black Triangle medicine like Wegovy, where post-market safety monitoring is ongoing.

What semaglutide does and doesn't do on its own

In the STEP 1 trial (a large phase-three study published in the New England Journal of Medicine) participants using semaglutide 2.4mg alongside lifestyle changes lost an average of around 15% of body weight over 68 weeks. The lifestyle component wasn't incidental. Semaglutide makes it considerably easier to eat less; it doesn't change what you eat, how you move or how you manage stress. People who maintain some attention to protein intake and physical activity tend to preserve more muscle mass during weight loss, which matters for long-term outcomes.

NICE's recommendation for semaglutide under technology appraisal TA875 specifies use within a specialist weight management service for a maximum of two years, and advises reviewing whether to continue if less than 5% weight loss has occurred after six months at the maintenance dose. Private treatment does not carry the two-year cap by regulatory mandate, but your prescriber will discuss what a realistic and appropriate treatment duration looks like for your situation.

If you'd like to explore what treatment through a clinician-led pharmacy looks like, our weight-loss treatment overview sets out the options. Or, if you have specific questions about any aspect of your medical history, our clinical team is available seven days a week.